新里程上半年实现营业收入15.88亿元 “医疗+医药”双轮驱动战略稳步推进

Core Viewpoint - New Mile Health Technology Group Co., Ltd. reported a revenue of 1.588 billion yuan and a net profit of 7.4311 million yuan for the first half of 2025, emphasizing its dual-driven strategy of "medical + pharmaceutical" for high-quality development [1] Group 1: Medical Services - The company focuses on a regional medical center strategy, establishing a "1+N" innovative service model based on tertiary general hospitals and specialized branches, as well as a new elderly care model combining elderly hospitals and care centers [1] - New Mile has established six regional medical centers in Liaoning, Henan, Jiangsu, Jiangxi, Sichuan, and Chongqing, with a total of 24 hospitals, including 4 tertiary hospitals and 13 secondary or higher comprehensive or specialized hospitals [1] - Several hospitals under New Mile, such as Lankao First Hospital and Wafangdian Third Hospital, have gained leading market shares through strategic restructuring and expansion, enhancing their competitiveness and profitability [2] Group 2: Pharmaceutical Sector - New Mile has developed a complete industrial chain for traditional Chinese medicine, centered around the "Duyiwei" brand, covering cultivation, sales, manufacturing, and distribution [3] - The completion of technological upgrades and capacity expansion at Duyiwei Pharmaceutical is expected to significantly increase the total output value of traditional Chinese medicine [3] - The clinical research on "Duyiwei" capsules combined with acupuncture for treating cervical spondylosis has successfully concluded, marking a new phase in the establishment of a scientific and standardized clinical evidence system [3]